Psychiatry · Medical Literature
[Articles] Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study
Abstract
GLP-1 receptor agonist treatment was associated with lower rates of hospitalisation in individuals with alcohol use disorder and substance use disorder. This association extended into the first 182 days after discontinuation for alcohol use disorder but not for substance use disorder. Findings support clinical monitoring of substance use when GLP-1 receptor agonist treatment is stopped.
Clinical relevance
Among individuals with type 2 diabetes, is GLP-1 receptor agonist treatment associated with lower rates of alcohol use disorder (AUD)-related and substance use disorder (SUD)-related hospital admissions during treatment and in the period following discontinuation? __SNAPSHOT__ {"studyDesign":"Register-based within-individual observational cohort study (each participant served as their own control, comparing treated vs. untreated periods within the same individual)","setting":"Sweden; national health registries (inpatient care, specialized outpatient care, and prescription registers)","sampleSize":"n=167,026 individuals with type 2 diabetes","population":"Adults with type 2 diabetes registered in Swedish national health databases who had documented GLP-1 receptor agonist prescriptions; individuals with co-occurring AUD and/or SUD were the primary analytical subgroup of interest","intervention":"GLP-1 receptor agonist treatment (class-level exposure; specific agents not disaggregated in the abstract)","comparator":"Treatment-free periods within the same individual (within-individual design; not a separate control group)","primaryOutcome":"AUD-related and SUD-related hospital admissions during GLP-1 RA treatment periods versus treatment-free periods, and during post-discontinuation windows (0–182 days and 183–365 days after stopping treatment)","followUp":"Post-discontinuation follow-up assessed at two windows: 0–182 days and 183–365 days after treatment cessation; total study period not reported in abstract","fundingSource":"Not reported in abstract; institutional affiliations include the Central Institute of Mental Health (CIMH), Germany, and Swedish academic institutions"}
Key findings
During active GLP-1 receptor agonist treatment periods, both AUD-related and SUD-related hospital admissions were significantly less frequent compared to treatment-free periods within the same individuals. For AUD-related hospitalizations, the protective association remained statistically significant during the first 182 days following treatment discontinuation but was no longer statistically significant in the 183–365-day post-discontinuation window, suggesting attenuation of effect within approximately one year of stopping. For SUD-related hospitalizations, no statistically significant association was observed after discontinuation in either post-treatment window (0–182 days or 183–365 days), indicating that the protective signal for non-alcohol substances did not extend beyond active treatment. Specific effect sizes (hazard ratios, rate ratios, confidence intervals, and p-values) are not reported in the abstract and were therefore not available for this summary. NNT and NNH cannot be calculated from available data. Adverse events are not reported in the abstract.
Practice implications
This study establishes an association between active GLP-1 receptor agonist treatment and reduced rates of AUD- and SUD-related hospitalizations in individuals with type 2 diabetes, extending prior register-based findings to the clinically important question of what happens after discontinuation. The within-individual design meaningfully reduces confounding from stable between-person characteristics (e.g., baseline severity, socioeconomic factors), which is a notable methodological strength over prior between-group comparisons. However, this remains an observational study, and causality cannot be inferred; unmeasured time-varying confounders (e.g., concurrent behavioral interventions, changes in social circumstances at the time of GLP-1 initiation or discontinuation) cannot be excluded. The population is restricted to individuals with type 2 diabetes, limiting direct generalizability to individuals with AUD or SUD who do not have diabetes or obesity. Whether findings extend to individuals on GLP-1 RAs for obesity indications alone is unknown. The differential post-discontinuation pattern—sustained signal for AUD but not SUD beyond 182 days—is hypothesis-generating and currently unexplained; mechanistic inferences should not be drawn from this data alone. Clinically, results support heightened monitoring for relapse in patients with co-occurring AUD or SUD when GLP-1 RA treatment is stopped, particularly in the first six months. Practice should not change with respect to prescribing GLP-1 RAs for AUD or SUD as primary indications; randomized controlled trials are required before such a recommendation can be made. Only the abstract was available for this summary, which limits full appraisal of statistical methods, covariate adjustment, sensitivity analyses, and adverse event reporting. __LIMITATIONS__ Observational design precludes causal inference; confounding by indication and time-varying confounders cannot be fully excluded.,Population restricted to individuals with type 2 diabetes; findings may not generalize to individuals with AUD or SUD without metabolic comorbidity.,Abstract-only availability: full statistical outputs (effect sizes, confidence intervals, p-values, sensitivity analyses) not accessible for this summary.,Within-individual design controls for time-stable confounders but not for time-varying factors (e.g., lifestyle changes, concurrent treatments, social support) that may coincide with GLP-1 initiation or discontinuation.,Hospitalization is a distal and relatively insensitive surrogate endpoint for alcohol and substance use; it may underestimate the true burden of AUD/SUD and miss meaningful changes in consumption or functioning.,Specific GLP-1 receptor agonists (e.g., semaglutide vs. liraglutide vs. dulaglutide) were not disaggregated in the abstract, yet prior data suggest agent-specific differences in effect magnitude.,Reasons for GLP-1 RA discontinuation (intentional cessation, adverse effects, cost, formulary changes) are not reported and may introduce informative censoring bias.,Generalizability is limited to the Swedish healthcare context and the specific time period of data collection; healthcare utilization patterns, prescribing practices, and AUD/SUD treatment access may differ in other countries.,Funding source not reported in abstract, precluding assessment of potential sponsorship bias. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In a large Swedish registry study of 167,026 individuals with type 2 diabetes, GLP-1 receptor agonist treatment was associated with fewer AUD-related and SUD-related hospitalizations during active treatment compared to treatment-free periods within the same individuals. The protective association for AUD persisted through the first 182 days post-discontinuation but dissipated by 12 months, while no significant post-discontinuation signal was observed for SUD. Pending confirmation from randomized trials, clinicians should consider proactive monitoring for AUD and SUD relapse in the first six months after GLP-1 RA treatment is stopped in patients with known comorbid substance use disorders.